BridgeBio Pharma, Inc. (BBIO) News

BridgeBio Pharma, Inc. (BBIO): $11.12

1.35 (+13.82%)

POWR Rating

Component Grades













Filter BBIO News Items

BBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BBIO News Highlights

  • BBIO's 30 day story count now stands at 2.
  • Over the past 13 days, the trend for BBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • ALTO are the most mentioned tickers in articles about BBIO.

Latest BBIO News From Around the Web

Below are the latest news stories about BRIDGEBIO PHARMA INC that investors may wish to consider to help them evaluate BBIO as an investment opportunity.

BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9 at 3:00 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the In

Yahoo | January 4, 2023

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations over a 24 week treatment period in patients with autosomal dominant hypocalcemia type 1 (ADH1) - The primary composite endpoint evaluates the proportion of participants with ADH1 achieving blood and urinary calcium within widely accepted normal ranges - In an ongoing single arm, open-label, Phase 2 saf

Yahoo | December 22, 2022

BridgeBio Pharma (NASDAQ:BBIO investor three-year losses grow to 81% as the stock sheds US$120m this past week

It's not possible to invest over long periods without making some bad investments. But really big losses can really...

Yahoo | December 20, 2022

Stealthy startup Apogee Therapeutics unveils $149M round to focus on inflammation and immunology

Led by a veteran of BridgeBio, the virtual company isn't saying much about the targets of its drugs, which were spun over to it by Paragon Therapeutics.

Yahoo | December 7, 2022

Inflammatory, immunological disease startup launches with $169M

A new startup is spinning out of Waltham-based antibody discovery company Paragon Therapeutics to develop new approaches to treating immunological and inflammatory diseases.

Yahoo | December 7, 2022

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Guardant Health (GH) and BridgeBio Pharma (BBIO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intuitive Surgical (ISRG – Research Report), Guardant Health (GH – Research Report) and BridgeBio Pharma (BBIO – Research Report) with bullish sentiments. Intuitive Surgical (ISRG) J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Intuitive Surgical yesterday and set a price target of $280.00. The company's shares closed last Thursday at $260.77. According to TipRanks.

Howard Kim on TipRanks | November 18, 2022

BridgeBio Pharma to Participate in November Investor Events

PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies Health Care Conference, London, UK: November 15th at 9:40 am ETEvercore ISI HealthCONx Conference, Virtual: November 30th at 10:05 am ET To access the live webcast

Yahoo | November 9, 2022

BridgeBio Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

BridgeBio Pharma ( NASDAQ:BBIO ) Third Quarter 2022 Results Key Financial Results Revenue: US$338.0k (down 86% from 3Q...

Yahoo | November 9, 2022

Mizuho Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on BridgeBio Pharma (BBIO - Research Report), with a price target of $23.00. The company's shares opened today at $10.02.Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to TipRanks, Syed has an average return of -16.2% and a 33.82% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BridgeBio Pharma with a $23.00 average price target, which is a 129.54% upside from current levels.

Jason Carr on TipRanks | November 7, 2022

BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5129 seconds.